BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In the aforementioned landmark analysis of >800 patients within the German CML IV study with BCR::ABL1IS results available at 3, 6, 12 and/or 24 months, 223 (28%) and 104 (12%) failed to achieve BCR::ABL1IS <10% at 3 and 6 months respectively, but remained on imatinib: the majority achieved this milestone at a later date [40, 41].